Replies to post #220641 on Biotech Values

[DewDiligence]

ACRX acquires TTPH in all-stock “takeunder” worth $0.65/sh—a 55% discount based on Friday’s closing prices of both stocks—excluding a tiered CVR based on sales milestones for Xerava:

https://www.businesswire.com/news/home/20200316005257/en/Tetraphase-Pharmaceuticals-AcelRx-Pharmaceuticals-Enter-Definitive-Merger

The nominal deal value is $14.4M, excluding the CVR.